News
Novavax joins Oxford mix-and-match COVID-19 vaccine study in adolescents
Biotech company Novavax will participate in the Oxford University-led Com-COV3 study, which is comparing a mixed COVID-19 vaccine schedule in adolescents.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Biotech company Novavax will participate in the Oxford University-led Com-COV3 study, which is comparing a mixed COVID-19 vaccine schedule in adolescents.